Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17535556 | 1.00 | NPSR1 (0.34) | NPSR1CHRM1HSD11B1LMNA | |
| SCHEMBL17535483 | 0.89 | LMNA (0.33) | NPSR1CHRM1LMNA | |
| SCHEMBL17535485 | 0.89 | LMNA (0.33) | NPSR1CHRM1LMNA | |
| SCHEMBL12807937 | 0.84 | NPSR1 (0.34) | NPSR1CHRM1HSD11B1LMNA | |
| SCHEMBL7949142 | 0.84 | NPSR1 (0.34) | NPSR1CHRM1HSD11B1LMNA | |
| SCHEMBL2445606 | 0.80 | NPSR1 (0.46) | NPSR1CHRM1HSD11B1LMNA | |
| SCHEMBL6856374 | 0.79 | NPSR1 (0.39) | NPSR1CHRM1HSD11B1LMNA | |
| SCHEMBL22280727 | 0.76 | SPHK1 (0.35) | NPSR1CHRM1HSD11B1LMNA | |
| SCHEMBL22347933 | 0.76 | SPHK1 (0.35) | NPSR1CHRM1HSD11B1LMNA | |
| SCHEMBL22353653 | 0.76 | SPHK1 (0.35) | NPSR1CHRM1HSD11B1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970331-B1 | SPIRO AZETIDINE ISOXAZOLE DERIVATIVES AND THEIR USE AS SSTR5 ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-05-17 | — | — | EP | disclosed |
| US-9605000-B2 | Spiro azetidine isoxazole derivatives and their use as SSTR antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-28 | — | — | US | disclosed |
| US-20160060273-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060273-A1 | HETEROCYCLIC COMPOUND | SSTR5, SSTR1, SSTR2 | NPSR1 19/4885CHRM1 1979/4885HSD11B1 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.